Article Details

Palisade Bio (NASDAQ:PALI) Rating Increased to Buy at Zacks Investment Research

Retrieved on: 2022-06-10 13:31:34

Tags for this article:

Click the tags to see associated articles and topics

Palisade Bio (NASDAQ:PALI) Rating Increased to Buy at Zacks Investment Research. View article details on HISWAI: https://www.defenseworld.net/2022/06/10/palisade-bio-nasdaqpali-rating-increased-to-buy-at-zacks-investment-research.html

Excerpt

Vanguard Group Inc. now owns 271,604 shares of the company's stock worth $288,000 after acquiring an additional 28,014 shares in the last quarter.

Article found on: www.defenseworld.net

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up